Delivered Q1 2026 revenue of $83.7 millionQ1 2026 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q1 2025Raising ...
A FAIR critique of “backward” exhibits must also reckon with how innovation evolves and how Zimbabwe can leapfrog without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results